Biomarkers Overview
Overview
Biomarkers Overview is a topic within the NeuroWiki knowledge base covering aspects of neurodegenerative disease research and mechanisms.
This section covers biomarkers for neurodegenerative disease diagnosis, progression, and therapeutic response. Biomarkers play a critical role in enabling early detection, accurate diagnosis, disease staging, and monitoring of therapeutic efficacy in neurodegenerative diseases.[@jack2018]
Major Biomarker Categories
Fluid Biomarkers
- Amyloid-beta — CSF and plasma Aβ42, Aβ40, and the Aβ42/40 ratio serve as core biomarkers for Alzheimer's disease pathology.[@blennow2015]
- Tau — Total tau and phosphorylated tau (p-tau) in CSF and plasma reflect neuronal damage and tau pathology burden.[@hampel2021]
- Neurofilament Light Chain (NfL) — A marker of axonal damage that elevates in multiple neurodegenerative conditions.[@khalil2018]
- Alpha-synuclein — CSF and plasma α-synuclein species, including oligomers and phosphorylated forms, for Parkinson's disease and related synucleinopathies.[@spiresjones2022]
...Biomarkers Overview
Overview
Biomarkers Overview is a topic within the NeuroWiki knowledge base covering aspects of neurodegenerative disease research and mechanisms.
This section covers biomarkers for neurodegenerative disease diagnosis, progression, and therapeutic response. Biomarkers play a critical role in enabling early detection, accurate diagnosis, disease staging, and monitoring of therapeutic efficacy in neurodegenerative diseases.[@jack2018]
Major Biomarker Categories
Fluid Biomarkers
- Amyloid-beta — CSF and plasma Aβ42, Aβ40, and the Aβ42/40 ratio serve as core biomarkers for Alzheimer's disease pathology.[@blennow2015]
- Tau — Total tau and phosphorylated tau (p-tau) in CSF and plasma reflect neuronal damage and tau pathology burden.[@hampel2021]
- Neurofilament Light Chain (NfL) — A marker of axonal damage that elevates in multiple neurodegenerative conditions.[@khalil2018]
- Alpha-synuclein — CSF and plasma α-synuclein species, including oligomers and phosphorylated forms, for Parkinson's disease and related synucleinopathies.[@spiresjones2022]
Imaging Biomarkers
- Amyloid PET — PET tracers such as florbetapir (Amyvid), flutemetamol (Vizamyl), and florbetaben (Neuraceq) enable in vivo visualization of amyloid plaques.[@vandenberghe2013]
- Tau PET — Second-generation tau PET tracers like flortaucipir (Tauvid), MK-6240, and PI-2620 allow quantification of tau neurofibrillary tangle burden.[@lockhart2022]
- FDG-PET — Fluorodeoxyglucose PET reveals regional hypometabolism patterns characteristic of different neurodegenerative syndromes.[@mosconi2005]
- MRI — Structural MRI for hippocampal atrophy, diffusion MRI for white matter integrity, and functional MRI for network connectivity.[@frisoni2010]
Genetic Biomarkers
- APOE — APOE ε4 allele is the strongest genetic risk factor for late-onset Alzheimer's disease.[@karch2015]
- LRRK2 — LRRK2 G2019S variant is the most common genetic cause of Parkinson's disease.[@cookson2015]
- C9orf72 — Hexanucleotide repeat expansion in C9orf72 causes familial ALS and frontotemporal dementia.[@baloh2012]
Biomarker Validation and Clinical Utility
The development of biomarkers for neurodegenerative diseases follows a systematic validation pathway from discovery through clinical implementation.[@forma2022]
Analytical Validation
- Precision: Assessment of assay reproducibility within and between laboratories using standardized protocols.
- Accuracy: Comparison of biomarker measurements against gold-standard methods.
- Stability: Evaluation of biomarker degradation under various pre-analytical conditions.
Clinical Validation
- Diagnostic accuracy: Sensitivity, specificity, and predictive values for distinguishing disease from controls.
- Disease progression markers: Correlation of biomarker levels with clinical decline and neuroimaging changes.
- Treatment response biomarkers: Ability to detect pharmacodynamic effects and predict clinical benefit.
Regulatory Approval
The FDA has approved several neuroimaging biomarkers for clinical use, including amyloid PET tracers for Alzheimer's disease diagnosis and the Lumipulse CSF biomarker tests for AD pathology detection.[@fda]
Disease-Specific Biomarker Panels
Alzheimer's Disease
The ATN (Amyloid, Tau, Neurodegeneration) framework provides a biological definition of AD based on biomarker profiles:[@jack2016]
- A (Amyloid): Aβ42, Aβ42/40 ratio, amyloid PET
- T (Tau): p-tau181, p-tau217, p-tau231, tau PET
- N (Neurodegeneration): total tau, FDG-PET, MRI atrophy, NfL
Emerging fluid biomarkers include neurogranin (synaptic dysfunction), YKL-40 (neuroinflammation), and GFAP (astrogliosis).[@milalom2020]
Parkinson's Disease and Synucleinopathies
- Alpha-synuclein seed amplification assays (RT-QuIC, PMCA) detect pathological α-synuclein with high sensitivity.[@fairfoul2016]
- Dopamine transporter imaging (DaT SPECT) demonstrates presynaptic dopaminergic degeneration.
- NfL serves as a progression marker in PD and predicts cognitive decline.[@parnetti2019]
Amyotrophic Lateral Sclerosis
- NfL and phosphorylated NfL (pNfH) are robust biomarkers of disease progression and survival.[@benatar2018]
- Neurofilament levels correlate with clinical measures and serve as endpoints in clinical trials.
Biomarker-Guided Clinical Trials
Biomarkers have transformed clinical trial design by enabling:[@cummings2023]
- Enrichment: Selecting patients based on biomarker-positive status for targeted therapies.
- Stratification: Subgrouping patients by biomarker profiles to identify treatment responders.
- Endpoint selection: Using biomarker changes as surrogate endpoints for clinical outcomes.
- Mechanistic confirmation: Demonstrating target engagement and biological activity of investigational therapies.
Technical Considerations
Sample Collection and Processing
- Standardized protocols for CSF collection, processing, and storage are essential for reproducible results.[@teunissen2015]
- Plasma biomarkers require careful consideration of assay platforms and reference standards.
Assay Standardization
- International standardization efforts, including the Global Alzheimer's Association Interactive Network (GAAIN) and the Alzheimer's Disease Neuroimaging Initiative (ADNI), promote harmonization across studies.[@standardization2017]
Future Directions
Multimodal Biomarker Integration
Combining fluid, imaging, and digital biomarkers through machine learning approaches promises more accurate diagnosis and prognosis.[@zhang2021]
Blood-Based Biomarkers
Plasma p-tau217, p-tau181, and NfL are approaching clinical utility for screening and diagnosis, potentially enabling population-scale detection of neurodegeneration.[@janelidze2021]
Digital Biomarkers
Smartphone-based cognitive assessments, wearable sensors for motor symptoms, and voice analysis offer continuous monitoring capabilities.[@artusi2020]
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
Topics
- [Biomarkers Overview](/biomarkers) — This page
- Biomarkers Rankings — Ranked list by research activity
- Biomarkers Dashboard — Data visualizations and metrics
Summary Statistics
- Total Pages: 101 Biomarkers pages in this section
- Last Updated: This section is actively maintained
A-Z All Pages
- 14-3-3 Proteins (CSF) - Biomarker
- 4R Tauopathy Differential Biomarkers
- AD Biomarker-to-Mechanism Mapping - Biomarker Guide
- Alpha-Synuclein - Biomarker
- Alpha-Synuclein Oligomers - Biomarker
- Alpha-Synuclein Seed Amplification Assay
- Alpha-Synuclein Seed Kinetic Staging in Parkinson's Disease
- Alpha-Synuclein Seeding Assays (RT-QuIC/PMCA)
- Alzheimer's Disease Biomarkers
- Alzheimer's Disease Biomarkers
- Amyloid Beta 40 (Aβ40) - Biomarker
- Aquaporin-4 (AQP4) - Glymphatic System Biomarker
- BDNF - Neurotrophic Factor Biomarker
- Beta-Amyloid 42/40 Ratio - Biomarker
- Beta-Synuclein (SNCB) - Biomarker
- Biomarker Rankings
- Biomarkers for Corticobasal Degeneration
- Biomarkers for Multiple System Atrophy
- Biomarkers for Progressive Supranuclear Palsy
- Biomarkers to Distinguish FTLD-tau from FTLD-TDP
- Blood-Based Biomarkers for Neurodegeneration
- CSF Biomarkers for Corticobasal Syndrome and Progressive Supranuclear Palsy
- CXCL12 (SDF-1) - Stromal Cell-Derived Factor 1
- Cell-Free DNA Biomarkers in Neurodegeneration
- Cerebrospinal Fluid (CSF) Biomarker Panels
- Cerebrospinal Fluid (CSF) Biomarkers Overview
- Chitotriosidase - Biomarker
- Clusterin (ApoJ) - Biomarker
- Complement Component 3 (C3)
- Contactin-1 - Biomarker for Peripheral Neuropathy
See all 101 biomarkers pages...
Allen Brain Atlas Resources
- [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
- [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
References
[Jack CR Jr, et al, NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29700479/)
[Blennow K, et al, CSF biomarkers: pinpointing earliest signs of Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25792536/)
[Hampel H, et al, Tau biomarkers in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33567279/)
[Khalil M, et al, Neurofilament light chain as a biological marker for neurological diseases (2018)](https://pubmed.ncbi.nlm.nih.gov/30091794/)
[Spires-Jones TL, et al, Alpha-synuclein: Pathology, biomarkers, and therapy (2022)](https://pubmed.ncbi.nlm.nih.gov/35278763/)
[Vandenberghe R, et al, Amyloid PET in clinical practice (2013)](https://pubmed.ncbi.nlm.nih.gov/23619269/)
[Lockhart SN, et al, Tau PET imaging: navigating complexity and new frontiers (2022)](https://pubmed.ncbi.nlm.nih.gov/34945099/)
[Mosconi L, FDG-PET: its role in the early diagnosis and differential diagnosis of Alzheimer's disease (2005)](https://pubmed.ncbi.nlm.nih.gov/15959401/)
[Frisoni GB, et al, The clinical use of structural MRI in Alzheimer disease (2010)](https://pubmed.ncbi.nlm.nih.gov/20122663/)
[Karch CM, Goate AM, Alzheimer's disease risk genes and mechanisms of disease pathogenesis (2015)](https://pubmed.ncbi.nlm.nih.gov/25526224/)
[Cookson MR, LRRK2 pathways to Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25433316/)
[Baloh RH, et al, C9orf72, the gene encoding dipeptide repeat proteins (2012)](https://pubmed.ncbi.nlm.nih.gov/22000309/)
[Forma EM, et al, Biomarker development for neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35130575/)
FDA, List of Cleared or Approved Companion Diagnostic Devices (n.d.)
[Jack CR Jr, et al, ATN: An Alzheimer's disease classification system (2016)](https://pubmed.ncbi.nlm.nih.gov/27440749/)
[Milà-Alomà M, et al, CSF synaptic biomarkers in the preclinical and prodromal stages of Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32958894/)
[Fairfoul G, et al, Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies (2016)](https://pubmed.ncbi.nlm.nih.gov/27264057/)
[Parnetti L, et al, CSF and blood biomarkers for Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31131648/)
[Benatar M, et al, Neurofilaments in ALS: a systematic review (2018)](https://pubmed.ncbi.nlm.nih.gov/29788986/)
[Cummings J, et al, Alzheimer's disease drug development pipeline: 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/36738347/)
[Teunissen CE, et al, Consensus guidelines for CSF and blood biomarker collection and analysis (2015)](https://pubmed.ncbi.nlm.nih.gov/25970387/)
[丸川 暁, et al, Standardization of biomarker measurement and reporting (2017)](https://pubmed.ncbi.nlm.nih.gov/28972927/)
[Zhang D, et al, Multimodal machine learning for Alzheimer's disease diagnosis (2021)](https://pubmed.ncbi.nlm.nih.gov/33437957/)
[Janelidze S, et al, Plasma P-tau181 in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33535278/)
[Artusi CA, et al, Digital biomarkers for Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32710965/)Pathway Diagram
Mermaid diagram (expand to render)
Pathway Diagram
The following diagram shows the key molecular relationships involving Biomarkers Overview discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)